Ondine Biomedical Inc.

TSX : OBP
AIM : OBP


Ondine Biomedical Inc.

March 21, 2011 08:00 ET

Ondine Announces Debt Financing

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 21, 2011) - Ondine Biomedical Inc. (TSX:OBP)(AIM:OBP) (the "Company" or "Ondine") a medical technology company developing photodisinfection based products, today announced that it has entered into a loan agreement with Carolyn Cross, Chairman, CEO and a shareholder of the Company, pursuant to which Ms. Cross advanced the Company C$500,000 (the "Loan"), demonstrating her continued support of the Company.

The Loan is due on July 1, 2011 and is secured by a first charge on the proceeds of any future financing transaction. The Loan is interest free until the due date, but thereafter, the principal amount will accrue interest at a rate of 5% per annum payable monthly. The proceeds of the Loan will be used for the continued research and development of new products based on the Company's photodisinfection technology, including the Endowave™ product for the reduction of ventilator associated pneumonia (VAP) and the Company's MRSAid™ product for the decolonization of pathogenic bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), in the nose; for working capital; and for general corporate purposes.

The loan agreement entered into by the Company and Ms. Cross constitutes a related party transaction for the purposes of the AIM Rules for Companies (the "Related Party Transaction"). Accordingly, the directors of the Company (excluding Ms. Cross), having consulted with its nominated adviser, consider the terms of the Related Party Transaction to be fair and reasonable insofar as the Company's shareholders are concerned.

The material change report in respect of this transaction was not filed at least 21 days in advance of the closing of the Loan as the Company was in need of the funds. The Company considers the shortened timeframe to be reasonable under these circumstances.

About Ondine Biomedical Inc.

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: www.ondinebio.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

Contact Information

  • Ondine Biomedical Inc.
    Carolyn Cross
    Chairman and CEO
    ccross@ondinebio.com
    www.ondinebio.com
    or
    Canaccord Genuity Limited, Nominated Adviser
    Mark Williams/Bhavesh Patel
    +4420 7050 6500